赛妥珠单抗聚乙二醇化治疗银屑病关节炎的RAPID-PsA 3期随机安慰剂对照试验4年结果
RAPID-PsA试验报告赛妥珠单抗聚乙二醇化(CZP)治疗银屑病关节炎患者4年的疗效、患者报告、影像学和安全性结局;216周时66.3%达到疾病活动指数低疾病活动度或缓解(NRI),39.2%达到最小疾病活动度(NRI),未发现新的安全性信号。
要点
- 第216周66.3%达到疾病活动指数低疾病活动度或缓解(NRI),第48周为60.4%。
- 第48周和第216周分别有39.2%达到最小疾病活动度(NRI)。
- 4年时附着点炎、指趾炎和甲银屑病完全缓解率分别为71%、81%和65%(LOCF)。
核心结论
- CZP治疗银屑病关节炎的疗效在4年内维持,无论既往是否暴露于抗TNF,且未发现新的安全性信号。
研究设计与样本
- RAPID-PsA(NCT01087788)为双盲、安慰剂对照至第24周,剂量盲至第48周,开放标签至第216周。
- 409例患者按1:1:1随机分配至安慰剂或CZP 200 mg每2周或400 mg每4周(第0/2/4周给予400 mg负荷剂量)。
- 随机分配至CZP的患者在开放标签期继续原剂量;随机分配至安慰剂的患者在第16周(早期 escape)或双盲期后重新随机分配至CZP 200 mg每2周或400 mg每4周(负荷剂量后)。
- 分类变量缺失值采用无应答者填补(NRI),连续变量采用末次观测值结转(LOCF)。
主要发现
- 第0周随机分配至CZP的273例患者中20%(54/273)有既往抗TNF暴露;67%(183/273)完成216周。
- 第48周60.4%达到疾病活动指数低疾病活动度或缓解,第216周66.3%达到这些结局(NRI)。
- 第48周和第216周分别有39.2%达到最小疾病活动度(NRI)。
- 银屑病面积和严重程度指数75%改善应答在第48周和第216周分别为65%和52%(NRI)。
- 4年时附着点炎、指趾炎和甲银屑病完全缓解率分别为71%、81%和65%(LOCF);4年治疗期间结构损伤进展低;第96周后未发现新的安全性信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the efficacy, patient-reported, radiographic and safety outcomes of 4 years' certolizumab pegol (CZP) treatment in patients with psoriatic arthritis (PsA). METHODS: RAPID-PsA (NCT01087788) was double-blind and placebo-controlled to Week 24, dose-blind to Week 48 and open-label (OL) to Week 216. Patients were randomised 1:1:1 to either placebo or CZP 200 mg every 2 weeks (Q2W) or 400 mg every 4 weeks (Q4W) (following 400 mg at Weeks 0/2/4). Patients randomised to CZP continued their assigned dose in the OL period. Patients randomised to placebo were re-randomised to CZP 200 mg Q2W or 400 mg Q4W (post-loading dose) at Week 16 (early escape) or after the double-blind phase. We present observed and imputed data; missing values were imputed using non-responder imputation (NRI) for categorical and last observation carried forward (LOCF) for continuous measures. RESULTS: 409 patients were randomised; 20% (54/273) of Week 0 patients randomised to CZP had prior anti-tumour necrosis factor (TNF) exposure; 67% (183/273) completed 216 weeks. By Week 48, 60.4% of patients achieved Disease Activity Index for Psoriatic Arthritis low disease activity or remission, which was maintained; 66.3% achieved these outcomes at Week 216 (NRI). At Weeks 48 and 216, 39.2% of patients achieved minimal disease activity (NRI). 75% reduction in Psoriasis Area and Severity Index responses were 65% and 52% at Weeks 48 and 216 (NRI). Total resolution rates for enthesitis, dactylitis and nail psoriasis, at 4 years, were 71%, 81% and 65%, respectively (LOCF). Structural damage progression was low over 4 years' treatment. No new safety signals were identified after Week 96. CONCLUSIONS: CZP efficacy in treating PsA was maintained over 4 years, in patients both with and without prior anti-TNF exposure, with no new safety signals identified.
引用
- van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 2018. PMID: 29556416. doi:10.1136/rmdopen-2017-000582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。